Pathogenic role of cGAS-STING pathway in Duchenne muscular dystrophy
En palabras de los autores
The cGAS-STING pathway is a critical component of the innate immune response to infection and cell stress. Chronic activation underlies human diseases such as lupus and inflammatory bowel disease, but cGAS-STING has not been implicated in Duchenne muscular dystrophy (DMD). Compared to healthy controls, macrophages from DMD patients have high levels of cytosolic DNA and low levels of the DNA exonuclease, TREX1, a scavenger of cytosolic DNA upstream of cGAS-STING. Likewise, cytosolic DNA is elevated in macrophages from dystrophin-deficient mdx mice. Such macrophages over-produce cGAMP and secrete it locally, activating STING in neighboring myoblasts and thereby suppressing myogenesis. TY1, a synthetic non-coding RNA drug that enhances TREX1, attenuates cGAS-STING and restores cellular and tissue homeostasis in mdx mice. When administered intravenously or orally, TY1 not only halted disease progression but actually reversed cardiac and skeletal muscle pathology. Thus, pathological activation of cGAS-STING by cytosolic DNA mediates disease progression in DMD. Our work identifies TREX1, cGAS and STING as novel therapeutic targets in muscular dystrophy.
Apareció: miércoles, 18 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.